aap Implantate AG · ISIN: DE000A3H2101 · EQS - Company News

Progress in the MDR process - important MDR initial certification audit carried out

aap Implantate AG ("aap" or "Company") has reached another important milestone in the transition from MDD (Medical Device Directive 93/42/EEC) to MDR (Medical Device Regulation EU 2017/745). In the week from 9 September 2024 to 13 September 2024, the Notified Body mdc medical device certification GmbH audited aap's quality system according to MDR. The audit was successfully completed. With this important milestone and the first positively audited technical documentation for its Class IIa product...

XETR:AAQ1 Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News aap Implantate AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (6)
Short Selling (DE) (0)
Short Selling (UK) (0)
07 October 2024 07:30AM
Progress in the MDR process - important MDR initial certification audit carried out
DE000A3H2101
aap Implantate AG ("aap" or "Company") has reached another important milestone in the transition from MDD (Medical Device Directive 93/42/EEC) to MDR (Medical Device Regulation EU 2017/745). In the week from 9 September 2024 to 13 September 2024, the Notified Body mdc medical device certification GmbH audited aap's quality system according to MDR. ...
aap Implantate AG
About the publication
24 September 2024 10:15PM
Very successful human clinical trial with the innovative antibacterial surface-treated implants receives approval for quick end of recruitment.
DE000A3H2101
BfArM and lead ethics committee approve early end of recruitment Last patient included on 6 August 2024; A total of 202 patients were included in the study; Start of the MDR registration phase aap Implantate AG ("aap" or "Company") informs that due to the ongoing good results the patient recruitment of the human clinical trial could be terminate...
aap Implantate AG
About the publication
23 August 2024 06:15PM
annual financial statements 2023 characterized by the difficult economic environment and restructuring measures introduced, good operational progress
DE000A3H2101
Financial year 2023 got off to a promising start for aap Implantate AG ("aap" or "Company"). Sales increased in all regions and exceeded the previous year's figures. The initial upswing lost momentum and the outlook in aap's sales markets gradually deteriorated due to financial difficulties in the healthcare sector and uncertainties about further e...
aap Implantate AG
About the publication
14 August 2024 07:15PM
Half-year financial statements close with balanced EBITDA, Trauma with positive EBITDA
DE000A3H2101
Sales: H1/2024 increased by 10% to EUR 6.4 million compared to H1/2023; main growth driver EMEA region EBITDA: H1/2024 breaks even, Trauma achieves positive EBITDA aap Implantate AG ("aap" or "Company") looks back on a pleasing first half-year. The Company was able to increase sales and EBITDA compared to the previous year and generate a positive ...
aap Implantate AG
About the publication
23 May 2024 07:05PM
Amendment of the terms and conditions of the bond completed; Bondholders can convert bonds into shares
DE000A3H2101
Notice to the Holders of the Mandatory Convertible Bond 2023/2028 (ISIN: DE000A351ZH9 / WKN: A351ZH)   aap Implantate AG announces today that the resolution adopted in the vote held without a meeting from March 26, 2024, to March 28, 2024, to cancel the vesting period regarding the conversion of the bonds and to allow a first-time conversion ri...
aap Implantate AG
About the publication
22 April 2024 07:30AM
aap closes Q1 2024 with sales growth of 5.6% and positive developments at all operating levels and makes a strong start to Q2 2024
DE000A3H2101
Sales increase by 5.6% compared to the same quarter of the previous year Major order and parts of Q1 sales form strong basis for growth in Q2 Human clinical trial of the innovative antibacterial implant technology is progressing positively and opens up the possibility of an earlier conclusion   aap Implantate AG ("aap" or "Company") continued it...
aap Implantate AG
About the publication
19 April 2024 07:30AM
aap successfully places a 10% capital increase from authorized capital at EUR 1.10 with exclusion of subscription rights
DE000A3H2101
The premium to the current share price of EUR 0.8 amounted to 37.5% The cash inflow will strengthen the company's own resources for the ongoing human clinical trial of the innovative antibacterial implant technology   aap Implantate AG ("aap" or "Company") successfully completed the 10% capital increase announced on March 18, 2024 with exclusion ...
aap Implantate AG
About the publication
17 April 2024 06:57PM
aap postpones publication of the consolidated financial statements 2023 due to staff shortages
DE000A3H2101
Publication of inside information in accordance with Article 17 of Regulation (EU) No 596/2014   aap postpones publication of the consolidated financial statements 2023 due to staff shortages   Berlin, 17. April 2024, time: 6:25 pm aap Implantate AG ("aap" or "Company") postpones the publication of the annual financial report for the financial...
aap Implantate AG
About the publication
03 April 2024 05:35PM
aap 100% approval of the proposed resolution to amend the terms and conditions of the mandatory convertible bond 2023/2028
DE000A3H2101
86.03% of the nominal amount and the votes of all outstanding bonds participated in the vote Approval by 100% of the votes cast aap Implantate AG ("aap" or "Company") successfully completed the vote without a meeting of bondholders on an amendment to the terms and conditions of the Bonds with an approval of 100% of the votes cast and the nominal v...
aap Implantate AG
About the publication
18 March 2024 12:35PM
Capital increase from authorized capital with exclusion of subscription rights
DE000A3H2101
Publication of inside information pursuant to Article 17 of Regulation (EU) No 596/2014 The Management Board of aap Implantate AG ("Company") resolved today, with the approval of the Supervisory Board, to increase the Company's share capital against cash contributions by issuing new no-par value bearer shares with a pro rata amount of the share c...
aap Implantate AG
About the publication
05 March 2024 12:18PM
aap proposes to the bondholders of the mandatory convertible bond 2023/2028 an amendment to the bond terms and conditions to enable the bondholders to exercise their conversion rights earlier
DE000A3H2101
aap Implantate AG ("aap" or "Company") proposes to the creditors of the mandatory convertible bond 2023/2028 (ISIN: DE000A351ZH9 / WKN: A351ZH) traded on the open market of the Frankfurt Stock Exchange to resolve on an amendment to the terms and conditions of the bond by way of a vote without a meeting of bondholders. The amendment to the terms and...
aap Implantate AG
About the publication
15 February 2024 01:04PM
After a mixed 2023 financial year, aap makes a strong start to the 2024 financial year
DE000A3H2101
Silver: significant acceleration in patient recruitment with over 130 patients as of the end of January 2024. Sales: very good start to the 2024 financial year Start of MDR certification In the past financial year, aap Implantate AG ("aap" or "Company") was able to significantly accelerate patient recruitment with the realignment of the world's f...
aap Implantate AG
About the publication
10 January 2024 07:30AM
More than 100 patients included in the human clinical trial by 31 December 2023; adapted study design meets expectations for accelerated patient recruitment
DE000A3H2101
EQS-Media / 10.01.2024 / 07:30 CET/CEST With regard to its innovative antibacterial implant technology, aap was able to successfully accelerate recruitment in the ongoing human clinical trial with the adapted study design in the course of 2023 and has already successfully recruited more than 100 patients by 31 December 2023. aap currently ass...
aap Implantate AG
About the publication
09 January 2024 07:30AM
aap concludes distribution agreement for LOQTEQ® VA Radius System with leading global spine and orthopedics company
DE000A3H2101
aap Implantate AG (“aap”) announces the conclusion of a distribution agreement for its LOQTEQ® VA Radius System with a leading global spine and orthopedics company. The distribution agreement for the LOQTEQ® VA Radius System, the top selling product of aap`s anatomical plates and screws portfolio, is exclusively distributed in the entire territory...
aap Implantate AG
About the publication
21 December 2023 12:46PM
Adjustment of the forecast for revenue and EBITDA for FY 2023; implementation of a personnel measure to achieve positive EBITDA and balanced cash flow in the operating trauma business
DE000A3H2101
  The Management Board of aap Implantate AG ("aap" or "Company") adjusts the forecast for sales and EBITDA for the financial year 2023. In addition, the Management Board today approved a package of measures for extensive staff reductions and further cost reductions. The Management Board expects sales of EUR 11.2 million to EUR 11.8 million for the ...
aap Implantate AG
About the publication
30 October 2023 11:44AM
Visible acceleration in clinical trial with already more than 60 patients; increase in funding of around EUR 0.4 million underscores innovative strength of silver coating technology
DE000A3H2101
  Clinical trial: Visible acceleration with already more than 60 patients recruited since clinical trial resumption in April; completion of patient recruitment planned in 2024 BMBF funding: increase in total funding by around EUR 0.4 million to up to EUR 3.1 million underscores the strategic innovative character of aap's antibacterial silver coat...
aap Implantate AG
About the publication
04 October 2023 07:58PM
aap places mandatory convertible bond 2023/2028 in the amount of EUR 2.5 million
DE000A3H2101
aap Implantate AG ("aap" or the "Company") today completed the placement of the mandatory convertible bond 2023/2028, which the Company's Management Board resolved to issue with the approval of the Supervisory Board on September 8, 2023. The issue met with a positive response from shareholders and new investors of aap in a capital market environmen...
aap Implantate AG
About the publication
08 September 2023 04:06PM
aap offers its shareholders a EUR 2.7 million mandatory convertible bond; subscription commitments of around 83% already received; accompanying restructuring measures in preparation
DE000A3H2101
The Management Board of aap Implantate AG ("aap" or the "Company") resolved today, with the approval of the Supervisory Board on the same day, to make use of the authorization granted by the Annual General Meeting on June 21, 2022 to issue convertible bonds and to issue a non-subordinated and unsecured mandatory convertible bond 2023/2028 in the to...
aap Implantate AG
About the publication
31 August 2023 07:43PM
Hiring of Jochen Rahner as Director Finance, IR and IT to succeed CFO Marek Hahn
DE000A3H2101
aap Implantate AG ("aap" or the "Company") announces that Mr. Jochen Rahner will succeed CFO Mr. Marek Hahn as Director Finance, IR and IT as of November 1, 2023. Mr. Rahner has over 20 years of financial experience in various functions and holds a degree in mechanical engineering. We are convinced that Mr. Rahner will confidently lead the areas of...
aap Implantate AG
About the publication
14 August 2023 12:17PM
Revenue growth in all regions (+8 %) and adjusted earnings improvement (EBITDA +21 %)
DE000A3H2101
  Sales: Q2 at EUR 2.9 million (+8 % yoy) and H1 at EUR 5.9 million (+6 % yoy); all regions in Q2 above previous year with LATAM (Q2: +13 %; H1: +29 % yoy) and North America (Q2: +7 %; H1: +11 % yoy) as main growth drivers EBITDA: improvement in Q2 (+21 %) with EUR ‑0.6 million (Q2/2022 corr.: EUR ‑0.7 million) and H1 (+13 %) with EUR ‑1.0 millio...
aap Implantate AG
About the publication
27 July 2023 04:39PM
Results of aap Implantate AG's Annual General Meeting underpin support for corporate strategy pursued
DE000A3H2101
  aap shareholders met for the Annual General Meeting in Berlin on July 25, 2023 Around 63 percent of the capital stock was represented at the Annual General Meeting All items on the agenda were approved with approval rates of >99 %  aap Implantate AG ("aap" or the "Company") had invited its shareholders to the Annual General Meeting on July ...
aap Implantate AG
About the publication
27 July 2023 04:39PM
Results of aap Implantate AG's Annual General Meeting underpin support for corporate strategy pursued
DE000A3H2101
  aap shareholders met for the Annual General Meeting in Berlin on July 25, 2023 Around 63 percent of the capital stock was represented at the Annual General Meeting All items on the agenda were approved with approval rates of >99 %  aap Implantate AG ("aap" or the "Company") had invited its shareholders to the Annual General Meeting on July ...
aap Implantate AG
About the publication
21 July 2023 06:54PM
No resolution on certain capital measures at the Annual General Meeting
DE000A3H2101
The Management Board of aap Implantate AG ("aap" or the "Company") today resolved to remove certain agenda items originally proposed for resolution at the Company's forthcoming Annual General Meeting on July 25, 2023 regarding Reduction of the share capital of the Company from EUR 8,955,849.00 by EUR 6,716,887.00 to EUR 2,238,962.00 (agenda items ...
aap Implantate AG
About the publication
21 July 2023 06:54PM
No resolution on certain capital measures at the Annual General Meeting
DE000A3H2101
The Management Board of aap Implantate AG ("aap" or the "Company") today resolved to remove certain agenda items originally proposed for resolution at the Company's forthcoming Annual General Meeting on July 25, 2023 regarding Reduction of the share capital of the Company from EUR 8,955,849.00 by EUR 6,716,887.00 to EUR 2,238,962.00 (agenda items ...
aap Implantate AG
About the publication
20 July 2023 07:30AM
Accelerated patient recruitment; adapted study protocol meets expectations for human clinical trial of breakthrough silver antibacterial coating technology
DE000A3H2101
  With regard to its innovative antibacterial silver coating technology, aap was able to successfully resume recruitment in the ongoing human clinical trial with an adapted study design and achieve a significant acceleration in patient recruitment after only a short time with the new study protocol. Currently, aap expects patient recruitment to be ...
aap Implantate AG
About the publication
20 July 2023 07:30AM
Accelerated patient recruitment; adapted study protocol meets expectations for human clinical trial of breakthrough silver antibacterial coating technology
DE000A3H2101
  With regard to its innovative antibacterial silver coating technology, aap was able to successfully resume recruitment in the ongoing human clinical trial with an adapted study design and achieve a significant acceleration in patient recruitment after only a short time with the new study protocol. Currently, aap expects patient recruitment to be ...
aap Implantate AG
About the publication
18 July 2023 07:30AM
US and LATAM businesses continue with double-digit growth; Q2 sales increase of +8%; solid growth of +6% in H1/2023
DE000A3H2101
Sales Q2: EUR 2.9 million (+8 % yoy); LATAM (+13 % yoy), USA (+7 % yoy) and EMEA (+6 % yoy, resulting from growth in Germany). Revenue half-year 2023: EUR 5.9 million (+6 % yoy); LATAM (+29 % yoy) and USA (+11 % yoy) with significant double-digit growth; EMEA at -3 % yoy, recovery trend after Q1 due to upturn in Q2. aap Implantate AG ("aap" or th...
aap Implantate AG
About the publication
18 July 2023 07:30AM
US and LATAM businesses continue with double-digit growth; Q2 sales increase of +8%; solid growth of +6% in H1/2023
DE000A3H2101
Sales Q2: EUR 2.9 million (+8 % yoy); LATAM (+13 % yoy), USA (+7 % yoy) and EMEA (+6 % yoy, resulting from growth in Germany). Revenue half-year 2023: EUR 5.9 million (+6 % yoy); LATAM (+29 % yoy) and USA (+11 % yoy) with significant double-digit growth; EMEA at -3 % yoy, recovery trend after Q1 due to upturn in Q2. aap Implantate AG ("aap" or th...
aap Implantate AG
About the publication
14 June 2023 07:30AM
Proposed capital measures in connection with the convening of the Annual General Meeting: Maintaining freedom of action in a macroeconomic environment characterized by high uncertainties
DE000A3H2101
The Management Board and Supervisory Board of aap Implantate AG ("aap" or the "Company") have, in the run-up to the adoption of the notice convening the Annual General Meeting to be held on July 25, 2023, intensively considered the Company's situation, its future development and the current and assumed macroeconomic environment in the further cours...
aap Implantate AG
About the publication
14 June 2023 07:30AM
Maintaining freedom of action in a macroeconomic environment characterized by high uncertainties
DE000A3H2101
The Management Board and Supervisory Board of aap Implantate AG ("aap" or the "Company") have, in the run-up to the adoption of the notice convening the Annual General Meeting to be held on July 25, 2023, intensively considered the Company's situation, its future development and the current and assumed macroeconomic environment in the further cours...
aap Implantate AG
About the publication
13 June 2023 04:51PM
Executive Board proposes in the invitation to the Annual General Meeting various capital measures for resolution
DE000A3H2101
The Management Board of aap Implantate AG ("aap" or the "Company") today resolved, with the consent of the Supervisory Board, to propose to the Company's Annual General Meeting to be convened on July 25, 2023, to resolve on the following capital measures: Reduction of the share capital of the Company from currently EUR 8,955,849.00 by EUR 6,716,88...
aap Implantate AG
About the publication
13 June 2023 04:51PM
Executive Board proposes in the invitation to the Annual General Meeting various capital measures for resolution
DE000A3H2101
The Management Board of aap Implantate AG ("aap" or the "Company") today resolved, with the consent of the Supervisory Board, to propose to the Company's Annual General Meeting to be convened on July 25, 2023, to resolve on the following capital measures: Reduction of the share capital of the Company from currently EUR 8,955,849.00 by EUR 6,716,88...
aap Implantate AG
About the publication
25 May 2023 05:52PM
aap CFO Marek Hahn ends his Management Board activities at the end of the year; contracts of CEO and COO extended until the end of 2025
DE000A3H2101
  CFO Marek Hahn recently informed the company of his wish not to accept the offered contract extension and to terminate his Executive Board activities as of Dec. 31, 2023 Dr. Nathalie Krebs, Chairwoman of the Supervisory Board, praises Hahn's "dedication, strategic clarity and leadership" CEO Rubino di Girolamo and COO Agnieszka Mierzejewska wi...
aap Implantate AG
About the publication
25 May 2023 05:52PM
aap CFO Marek Hahn ends his Management Board activities at the end of the year; contracts of CEO and COO extended until the end of 2025
DE000A3H2101
  CFO Marek Hahn recently informed the company of his wish not to accept the offered contract extension and to terminate his Executive Board activities as of Dec. 31, 2023 Dr. Nathalie Krebs, Chairwoman of the Supervisory Board, praises Hahn's "dedication, strategic clarity and leadership" CEO Rubino di Girolamo and COO Agnieszka Mierzejewska wi...
aap Implantate AG
About the publication
15 May 2023 10:32AM
Q1/2023: Solid start with slight sales growth (+3 %) and unchanged EBITDA; US and LATAM business grow well into double digits
DE000A3H2101
  Sales: EUR 3.0 million (+3 % yoy; CER[1] : +2 % yoy); LATAM (+55 % yoy) and USA (+15 % yoy) with significant double-digit growth; EMEA with -9 % yoy remains below expectations EBITDA unchanged year-on-year at EUR -0.5 million in cost- and interest-rate-inflationary environment; operating cash flow +74 % year-on-year Silver: Clinical trial resu...
aap Implantate AG
About the publication
15 May 2023 10:32AM
Solid start with slight sales growth (+3 %) and unchanged EBITDA; US and LATAM business grow well into double digits
DE000A3H2101
  Sales: EUR 3.0 million (+3 % yoy; CER[1] : +2 % yoy); LATAM (+55 % yoy) and USA (+15 % yoy) with significant double-digit growth; EMEA with -9 % yoy remains below expectations EBITDA unchanged year-on-year at EUR -0.5 million in cost- and interest-rate-inflationary environment; operating cash flow +74 % year-on-year Silver: Clinical trial resu...
aap Implantate AG
About the publication
28 April 2023 11:50AM
Consolidation in FY/2022: Small decline in sales with stable cost base and strong improvement in operating cash flow (+23 %) in challenging environment
DE000A3H2101
  Sales: EUR 11.5 million (-6 % yoy; CER[1] : -9 % yoy); markets generally in difficult environment with mixed results; USA in H2/2022 with solid growth and excluding one-off effects +16 % yoy EBITDA: EUR -1.7 million (FY/2021: EUR -0.8 million); operating cash flow +23 % yoy Silver: Release revised study protocol in Q4/2022 with restart study i...
aap Implantate AG
About the publication
28 April 2023 11:50AM
Small decline in sales with stable cost base and strong improvement in operating cash flow (+23 %) in challenging environment
DE000A3H2101
  Sales: EUR 11.5 million (-6 % yoy; CER[1] : -9 % yoy); markets generally in difficult environment with mixed results; USA in H2/2022 with solid growth and excluding one-off effects +16 % yoy EBITDA: EUR -1.7 million (FY/2021: EUR -0.8 million); operating cash flow +23 % yoy Silver: Release revised study protocol in Q4/2022 with restart study i...
aap Implantate AG
About the publication
03 April 2023 07:30AM
aap Implants Inc. awarded agreement with Premier, Inc. for Small Joint Implants – Upper Extremities, Small Joint Implants – Lower Extremities, Podiatry Products and Accessories
DE000A3H2101
aap Implantate AG (“aap”) announces that its US subsidiary aap Implants Inc has been awarded a group purchasing agreement for the “Small Joint Implants – Upper Extremities” “Small Joint Implants - Lower Extremities, Podiatry Products and Accessories” portfolio with Premier, Inc., effective as of March 1, 2023. The agreement allows Premier members, ...
aap Implantate AG
About the publication
03 April 2023 07:30AM
aap Implants Inc. awarded agreement with Premier, Inc. for Small Joint Implants – Upper Extremities, Small Joint Implants – Lower Extremities, Podiatry Products and Accessories
DE000A3H2101
aap Implantate AG (“aap”) announces that its US subsidiary aap Implants Inc has been awarded a group purchasing agreement for the “Small Joint Implants – Upper Extremities” “Small Joint Implants - Lower Extremities, Podiatry Products and Accessories” portfolio with Premier, Inc., effective as of March 1, 2023. The agreement allows Premier members, ...
aap Implantate AG
About the publication
21 March 2023 09:08AM
aap receives US-American clearance (FDA) for polyaxial LOQTEQ® VA Elbow system; launch planned for Q4 2023
DE000A3H2101
aap Implantate AG (“aap”) announces that its new system LOQTEQ® VA Elbow 2.7/3.5 has been cleared by the US-American Food and Drug Administration (FDA). The Company plans to launch the system LOQTEQ® VA Elbow 2.7/3.5 in the fourth quarter of 2023 in the United States and in other markets that accept FDA clearances. The system enables flexible treat...
aap Implantate AG
About the publication
21 March 2023 09:08AM
aap receives US-American clearance (FDA) for polyaxial LOQTEQ® VA Elbow system; launch planned for Q4 2023
DE000A3H2101
aap Implantate AG (“aap”) announces that its new system LOQTEQ® VA Elbow 2.7/3.5 has been cleared by the US-American Food and Drug Administration (FDA). The Company plans to launch the system LOQTEQ® VA Elbow 2.7/3.5 in the fourth quarter of 2023 in the United States and in other markets that accept FDA clearances. The system enables flexible treat...
aap Implantate AG
About the publication
15 March 2023 08:17PM
capital measure fully subscribed; issue of 2.4 million new shares leads to gross issue proceeds of around EUR 3.3 million
DE000A3H2101
The Management Board of aap Implantate AG ("aap" or the "Company") announces that, following completion of the private placement as part of the capital increase with subscription rights, the capital measure has been fully subscribed. The Management Board of the Company participated in the capital measure to the extent of EUR 0.4 million. On 15 Marc...
aap Implantate AG
About the publication
15 March 2023 08:17PM
Result of the capital increase with subscription rights: capital measure fully subscribed; issue of 2.4 million new shares leads to gross issue proceeds of around EUR 3.3 million
DE000A3H2101
The Management Board of aap Implantate AG ("aap" or the "Company") announces that, following completion of the private placement as part of the capital increase with subscription rights, the capital measure has been fully subscribed. The Management Board of the Company participated in the capital measure to the extent of EUR 0.4 million. On 15 Marc...
aap Implantate AG
About the publication
21 February 2023 01:16PM
Good start in 2023 after challenging fiscal year 2022
DE000A3H2101
  Sales: Good start in January 2023 in the U.S. with double-digit sales growth; international distributors confident of sales expansion in 2023 Silver: Restart of human clinical trial after approved clinical trial protocol amendment in April 2023; significant acceleration in patient recruitment expected Successful start of capital increase with ...
aap Implantate AG
About the publication
21 February 2023 01:16PM
Good start in 2023 after challenging fiscal year 2022
DE000A3H2101
  Sales: Good start in January 2023 in the U.S. with double-digit sales growth; international distributors confident of sales expansion in 2023 Silver: Restart of human clinical trial after approved clinical trial protocol amendment in April 2023; significant acceleration in patient recruitment expected Successful start of capital increase with ...
aap Implantate AG
About the publication
21 February 2023 12:48PM
aap Implantate AG resolves on capital increase with subscription rights to strengthen its financial base
DE000A3H2101
The Management Board of aap Implantate AG (“aap” or the “Company”) resolved on 21 February 2023 with the approval of the Supervisory Board on the same day on a capital increase against cash contributions out of the authorized capital 2022/I with subscription and oversubscription rights of the shareholders of the Company. aap’s share capital shall b...
aap Implantate AG
About the publication
21 February 2023 12:48PM
aap Implantate AG resolves on capital increase with subscription rights to strengthen its financial base
DE000A3H2101
The Management Board of aap Implantate AG (“aap” or the “Company”) resolved on 21 February 2023 with the approval of the Supervisory Board on the same day on a capital increase against cash contributions out of the authorized capital 2022/I with subscription and oversubscription rights of the shareholders of the Company. aap’s share capital shall b...
aap Implantate AG
About the publication
More aap Implantate AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 6 15th June 2023 di Girolamo, Rubino DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN